Vaccines for Breast and Ovarian Cancer Yield Triumphant Results

Recommend to others!

With the increasing number of diseases which affects the human population, the medical health professionals, scientists and researchers are doing their best effort and ways in preventing these diseases from affecting the general public. One way is through vaccination which can offer significant health benefits by boosting the immune system and providing protection for a span of time even for about life time to all individuals who received vaccination shots. Recently, a clinical trial was done to observe the efficacy and effectiveness of metastatic breast and ovarian cancer vaccine, and results show its promising response.

Breast cancer is a malignancy of breast cells which is often associated with a lot of health risk factors. Women are the most population affected with this health problem, but men can also be affected. The prognosis of individuals who have this disease varies on the size, stage, rate of growth and the characteristic of the tumor. On the other hand, ovarian cancer usually happens in women over the age of 50, but it can also affect younger women. Its cause is unknown. Ovarian cancer is hard to detect early. Treatment for both diseases includes: chemotherapy, radiation therapy, and surgery.

The result of the clinical trial was published in Clinical Cancer Research. The clinical trial using vaccine for both metastatic breast and ovarian cancer showed a positive response and the standard side effect noted was just mild reactions from the injection site. The said vaccine was composed of a recombinant poxviral vaccine.

The clinical trial involved the analysis and examination of results from about 26 study participants who were having the disease and were treated prior to the administration of vaccines. About 21 study participants actually received at least three chemotherapy treatments. The study participants were assigned to receive vaccination shots of PANVAC vaccine every month. The said vaccine is composed of transgenes for MUC-1, CEA and three T cell costimulatory molecules.

Moreover, The researchers found out that among the study participants, 12 patients who are having breast cancer have been reported to have a disease progression of about an average time of 2 and a half months, and a general average survivability rate of about 13.7 months. In addition, those patients who have ovarian cancer had a disease progression of an average time about 2 months and overall average survivability rate of 15 months. Although, the trial showed promising results to enhance treatment outcomes, still further studies must be establish in order to make recommendations for the use of vaccine.

According to the National Institutes of Health, the sooner ovarian cancer is found and treated, the better your chance for recovery. But ovarian cancer is hard to detect early. Many times, women with ovarian cancer have no symptoms or just mild symptoms until the disease is in an advanced stage and hard to treat. Symptoms may include:

-          Heavy feeling in pelvis

-          Pain in lower abdomen

-          Bleeding from the vagina

-          Weight gain or loss

-          Abnormal periods

-          Unexplained back pain that gets worse

-          Gas, nausea, vomiting, or loss of appetite




Speak Your Mind


Current day month ye@r *